BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 16822308)

  • 21. Frequent PIK3CA activating mutations in nipple adenomas.
    Liau JY; Lee YH; Tsai JH; Yuan CT; Chu CY; Hong JB; Sheen YS
    Histopathology; 2017 Jan; 70(2):195-202. PubMed ID: 27441415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
    Migliardi G; Sassi F; Torti D; Galimi F; Zanella ER; Buscarino M; Ribero D; Muratore A; Massucco P; Pisacane A; Risio M; Capussotti L; Marsoni S; Di Nicolantonio F; Bardelli A; Comoglio PM; Trusolino L; Bertotti A
    Clin Cancer Res; 2012 May; 18(9):2515-25. PubMed ID: 22392911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas.
    Suenaga Y; Islam SM; Alagu J; Kaneko Y; Kato M; Tanaka Y; Kawana H; Hossain S; Matsumoto D; Yamamoto M; Shoji W; Itami M; Shibata T; Nakamura Y; Ohira M; Haraguchi S; Takatori A; Nakagawara A
    PLoS Genet; 2014 Jan; 10(1):e1003996. PubMed ID: 24391509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia.
    Case M; Matheson E; Minto L; Hassan R; Harrison CJ; Bown N; Bailey S; Vormoor J; Hall AG; Irving JA
    Cancer Res; 2008 Aug; 68(16):6803-9. PubMed ID: 18701506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic strategies for targeting BRAF in human cancer.
    Pratilas CA; Solit DB
    Rev Recent Clin Trials; 2007 May; 2(2):121-34. PubMed ID: 18473997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification.
    Liu X; Mazanek P; Dam V; Wang Q; Zhao H; Guo R; Jagannathan J; Cnaan A; Maris JM; Hogarty MD
    Oncogene; 2008 Feb; 27(10):1478-88. PubMed ID: 17724465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas, and medullary thyroid cancers.
    Moley JF; Brother MB; Wells SA; Spengler BA; Biedler JL; Brodeur GM
    Cancer Res; 1991 Mar; 51(6):1596-9. PubMed ID: 1998949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CNS germinomas are characterized by global demethylation, chromosomal instability and mutational activation of the Kit-, Ras/Raf/Erk- and Akt-pathways.
    Schulte SL; Waha A; Steiger B; Denkhaus D; Dörner E; Calaminus G; Leuschner I; Pietsch T
    Oncotarget; 2016 Aug; 7(34):55026-55042. PubMed ID: 27391150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin.
    Growdon WB; Roussel BN; Scialabba VL; Foster R; Dias-Santagata D; Iafrate AJ; Ellisen LW; Tambouret RH; Rueda BR; Borger DR
    Gynecol Oncol; 2011 Apr; 121(1):212-7. PubMed ID: 21168197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells.
    Schulte JH; Lindner S; Bohrer A; Maurer J; De Preter K; Lefever S; Heukamp L; Schulte S; Molenaar J; Versteeg R; Thor T; Künkele A; Vandesompele J; Speleman F; Schorle H; Eggert A; Schramm A
    Oncogene; 2013 Feb; 32(8):1059-65. PubMed ID: 22484425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.
    Burger M; Denzinger S; Hammerschmied C; Tannapfel A; Maderstorfer A; Wieland WF; Hartmann A; Stoehr R
    Eur Urol; 2006 Nov; 50(5):1102-9; discussion 1109-10. PubMed ID: 16413100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR, PIK3CA and PTEN gene status and their protein product expression in neuroblastic tumours.
    Izycka-Swieszewska E; Brzeskwiniewicz M; Wozniak A; Drozynska E; Grajkowska W; Perek D; Balcerska A; Klepacka T; Limon J
    Folia Neuropathol; 2010; 48(4):238-45. PubMed ID: 21225506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.
    McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Montalto G; Cervello M; Nicoletti F; Fagone P; Malaponte G; Mazzarino MC; Candido S; Libra M; Bäsecke J; Mijatovic S; Maksimovic-Ivanic D; Milella M; Tafuri A; Cocco L; Evangelisti C; Chiarini F; Martelli AM
    Oncotarget; 2012 Sep; 3(9):954-87. PubMed ID: 23006971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
    Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY
    Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
    Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
    Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma.
    Sommerer F; Vieth M; Markwarth A; Röhrich K; Vomschloss S; May A; Ell C; Stolte M; Hengge UR; Wittekind C; Tannapfel A
    Oncogene; 2004 Jan; 23(2):554-8. PubMed ID: 14724583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc.
    Yaari-Stark S; Shaked M; Nevo-Caspi Y; Jacob-Hircsh J; Shamir R; Rechavi G; Kloog Y
    Int J Cancer; 2010 May; 126(10):2268-81. PubMed ID: 19998334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence.
    Thompson KN; Whipple RA; Yoon JR; Lipsky M; Charpentier MS; Boggs AE; Chakrabarti KR; Bhandary L; Hessler LK; Martin SS; Vitolo MI
    Oncotarget; 2015 Nov; 6(34):35231-46. PubMed ID: 26497685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
    Oda K; Okada J; Timmerman L; Rodriguez-Viciana P; Stokoe D; Shoji K; Taketani Y; Kuramoto H; Knight ZA; Shokat KM; McCormick F
    Cancer Res; 2008 Oct; 68(19):8127-36. PubMed ID: 18829572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.